Post Traumatic Stress Disorder Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

Market Overview

The post-traumatic stress disorder treatment market is expected to register a CAGR of 4.35% during the forecast period, 2022 - 2027.

COVID-19 has considerably impacted the demand for post-traumatic stress disorder (PTSD) treatment due to the rise in stress among patients regarding the COVID-19 pandemic. For instance, according to the study published in the International Journal of Mental Health Nursing, titled "Impact of COVID‐19 on post‐traumatic stress symptoms in the general population: An integrative review" in April 2021, in most investigations, a high and wide range of PTSD rates were recorded. Similar to the findings of studies on other infectious diseases, the study concluded that the post-traumatic stress symptoms impacted the entire population exposed to the SARS-CoV-2 virus. Furthermore, according to the study published in the Journal of Affective Disorders, titled "The prevalence of post-traumatic stress disorder related symptoms in Coronavirus outbreaks: A systematic review and meta-analysis", in January 2021, the prevalence of PTSD symptoms was estimated to be about 18%. This is expected to increase the adoption of PTSD therapies during the pandemic phase, which in turn has a positive impact on the market growth.

Further, the major factors driving the market's growth include a rise in the burden of post-traumatic stress disorders across the globe, growth in research and development for PTSD, a surge in product launches and developments, and an increasing number of strategic initiatives undertaken by key market players.

An upsurge in the incidences of post-traumatic stress disorders worldwide is one of the major factors driving the market growth. For instance, according to the post-traumatic stress disorder factsheet published in October 2021 by NeuRA (Neuroscience Research Australia), the general population's lifetime prevalence of PTSD was approximately 3.9 percent. In those who had been exposed to trauma, the rate was 5.6 percent. The prevalence of PTSD in people who have been subjected to purposeful traumas such as war and assault (rather than non-intentional traumas such as accidents and natural catastrophes) increased, with rates rising from 11.8 percent in one month to 23.3 percent in one-year post-trauma. Thus, such a growing prevalence of PTSD is anticipated to impact the market's growth positively.

Additionally, the rise in research and development activities by the key market players will lead to an increase in clinical trials for the development of PTSD drugs, ultimately boosting the commercial availability of products within the market. For instance, in December 2021, Jazz Pharmaceuticals plc was enrolled in a Phase 2 clinical trial evaluating the safety and efficacy of JZP150, an investigational first-in-class small molecule for the treatment of adults with post-traumatic stress disorder (PTSD). Therefore, a rise in clinical trials, growth in research and development activities, and a surge in the prevalence of PTSD are all collectively expected to drive this market's growth.

However, a lack of awareness among people about PTSD treatments, as well as side effects associated with PTSD therapeutics, is expected to hinder the market's growth during the analysis period.

Scope of the Report

As per the scope of the report, post-traumatic stress disorder (PTSD) is a treatable anxiety disorder caused due to fear, anxiety, and memories of a traumatic event. It is characterized by symptoms such as flashbacks, nightmares, and severe anxiety, as well as uncontrollable thoughts about the event. People who have encountered or witnessed a traumatic incident such as a natural disaster, a catastrophic accident, a terrorist attack, war/combat, or who have been threatened with death, sexual violence, or serious injury may develop post-traumatic stress disorder (PTSD). The market is segmented by Drug Type (Antidepressants, Monoamine Oxidase Inhibitors, Antipsychotics or Second-Generation Antipsychotics, Beta-blockers, Benzodiazepines, Others), Age Group (Adult and Children), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.

Report scope can be customized per your requirements. Click here.

Key Market Trends

Antipsychotics or Second generation Antipsychotics Drugs Segment Is Expected To Hold A Major Share In The Market Studied

By drug type, the antipsychotics or second-generation antipsychotic drugs segment is expected to hold a major share in the post-traumatic stress disorder treatment market owing to the rise in the adoption of antipsychotic drugs for the treatment of PTSD and PTSD-related symptoms.

The presence of psychotic symptoms in individuals suffering from PTSD has led researchers to encourage the recognition of a variant of PTSD known as PTSD with psychotic features and its subsequent treatment with antipsychotic medication. A typical antipsychotic has been shown to be effective in the treatment of PTSD in several studies. While some studies show an improvement in sleep patterns, including a decrease in nightmares, others show an improvement in flashbacks and intrusive thoughts. Likewise, as per a study published in Frontiers in Pharmacology, titled "Comparative Efficacy and Acceptability of Pharmaceutical Management for Adults With Post-Traumatic Stress Disorder: A Systematic Review and Meta-Analysis" in May 2020, a typical antipsychotic showed considerable efficacy when compared to placebo in patients with severe or extremely severe PTSD. The substantial effectiveness of antipsychotics in PTSD will lead to increased adoption of antipsychotics for the treatment of PTSD, driving this segment's growth.

In addition, according to study results presented at Psych Congress 2021 in San Antonio, Texas, adjunctive bexpiprazole (an antipsychotic drug) may help individuals with symptoms of anxious distress disorders such as PTSD. Furthermore, key market players are developing antipsychotic drugs for the treatment of PTSD. For instance, Otsuka Holding is developing Rexulti (bexpiprazole), and the molecule is under phase III clinical studies as of March 2022.

Therefore, the increasing adoption of antipsychotic drugs for the treatment of PTSD, the rise in clinical trials for antipsychotic drugs, and the notable efficacy of antipsychotics in the treatment of PTSD are the factors expected to drive the growth of this segment over the forecast period.

To understand key trends, Download Sample Report